Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

NCT03602508 · clinicaltrials.gov ↗

COMPLETED

Status

5589

Enrollment

INDUSTRY

Sponsor class

Conditions

Overactive Bladder (OAB)

Interventions

DRUG: mirabegron
DRUG: solifenacin
DRUG: darifenacin
DRUG: imidafenacin
DRUG: tolterodine
DRUG: oxybutynin
DRUG: trospium
DRUG: fesoterodine
DRUG: propiverine

Sponsor

Astellas Pharma Singapore Pte. Ltd.